Physician profile
Dean Watzman
NPI 1497738967
$4,668.07
in general payments reported to CMS, 2019-2025
22 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2021: $1,046 · 2022: $756 · 2023: $247 · 2024: $1,249 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,032 · Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,031.69 |
| Food and Beverage | $680.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,045.06 | 2021-2024 | Single Use Suction Valve (Sterile) |
| Glaxosmithkline, LLC. | $1,352.17 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $250.31 | 2019-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.42 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Combivent Respimat |
| Genzyme Corporation | $161.58 | 2019-2021 | |
| Pfizer INC. | $134.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $85.80 | 2019-2025 | Dupixent |
| Gilead Sciences, INC. | $55.02 | 2019 | |
| Shire North American Group INC | $39.62 | 2019 | |
| Philips North America LLC | $39.59 | 2019 | |
| Grifols USA, LLC | $39.27 | 2019 | |
| Insmed, INC. | $38.16 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $32.16 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $23.60 | 2025 | Terlivaz |
| Jazz Pharmaceuticals INC. | $22.71 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $19.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.00 | 2019 | |
| Merck Sharp & Dohme LLC | $17.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.80 | 2019 | |
| Mylan Specialty L.P. | $15.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.13 | 2019 | |
| Genentech USA, INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Watzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.